trending Market Intelligence /marketintelligence/en/news-insights/trending/dhsgwudvyej2m8ywkd0emq2 content esgSubNav
In This List

US FDA rejects Amgen's application for Herceptin biosimilar

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


US FDA rejects Amgen's application for Herceptin biosimilar

The U.S. Food and Drug Administration rejected Amgen Inc.'s application seeking approval for ABP 980, a biosimilar version of Herceptin.

"We will work closely with the FDA to bring this important medicine to patients in the U.S. We do not expect this to impact our U.S launch plan," Amgen said in a statement.

Herceptin, or trastuzumab, which is owned by Roche Holding AG, generated CHF 7.01 billion in sales during 2017.